There is an increasing pressure for the medical industry to confront the vital challenge of advancing manufacturing processes for Cell and Gene Therapy. CGT is widely regarded as the future of medicine, but innovation is hindered by slow, laborious and expensive sterility testing. This whitepaper goes behind the scenes of a significant breakthrough for contamination detection in CGT monitoring. It tells the story of PureSentry, a prototype device for on-line, real-time detection. 

The breakthrough system demonstrates that contaminants which cause cell therapy batches to fail can be detected in a fully automated process at a cost several orders of magnitude below the current cost of a cell therapy treatment. Adopting such an approach could save manufacturers money and help deliver therapies to patients sooner. And all at unprecedented scale.  

Download the whitepaper below for an informative and comprehensive guide to the development, which also stands as a proof of concept for event-based cameras in rapid microbial detection and a study in how AI can be applied to solve problems in industry 4.0. 

Scroll down to download the whitepaper 

Download now

Media downloads

PureSentry-Whitepaper.pdf
Author
Matthew Jones
Principal Synthetic Biologist

Matthew Jones is a Principal Synthetic Biologist at Cambridge Consultants delivering projects for clients working at the interface between biotechnology and engineering. Matthew is also supporting the development of our internal capabilities in cell free biology, laboratory automation and design of experiment approaches.